Statement of Financial Position	Sch	As at	As at
		31 March 2023	31 March 2022
ASSETS		EUR	(Amt in LCY)
Current assets			
Cash and cash equivalents	A	1.020.088,77	712.192,47
Trade receivable	C	1.722.016,22	1.384.981,91
Inventories	D	1.573.185,20	1.448.008,96
Other current financial assets	E	2.287,79	-
Other current assets	F	35.861,65	72.886,91
Total current assets		4.353.439,63	3.618.070,25
Non-current assets			
Property, plant and equipment	G	43.445,34	35.794,77
Right to use asset	H1	200.097,00	131.616,00
Intangible Assets	I	77.672,12	69.336,48
Goodwill	I	_	-
Deferred tax assets (net)	Y	1.533,00	200,00
Investments	L	1	,
Non-current financial assets	L	127.349,48	136.339,53
Other non-current assets	J		375,88
Total non-current assets		450.096,94	373.662,66
Total assets		4.803.536,57	3.991.732,91
LIABILITIES AND STOCKHOLDERS' E	YTIUÇ		
Current liabilities	_		
Trade payables	M	2.342.009,25	1.996.825,11
Current tax liabilities		43.452,01	74.787,25
Short-term borrowings	0	_	-
Current portion of long term borrowing	P	_	_
Other current liabilities	Q	42.994,42	39.170,95
Other current financial liabilities	R	437.079,11	266.252,60
Lease liability - current	H2	95.912,00	62.816,00
Provisions	S	-	-
Total current liabilities		2.961.446,79	2.439.851,91
Non-current liabilities			,
Long-term borrowings	T		
Lease liability - non current	H2	111.204,000	70.026,000
Other non-current liabilities	U	-	-
Other non-current financial liabilities	v	_	_
Total non-current liabilities		111.204,00	70.026,00
Total liabilities		3.072.650,79	2.509.877,91
Stockholders' equity			
Equity share capital	W	3.000,00	3.000,00
Share premium			
Stock compensation reserve			
Statutory reserve			
Currency translation reserve			
Retained earnings	W	1.727.885,78	1.478.855,00
Non-controlling interest			-
Total stockholders' equity		1.730.885,78	1.481.855,0
Total liabilities and stockholders'			
equity		4.803.536,57	3.991.732,9

MARTIN BALERIOLA JORGE MANUEL -07238112N Firmado digitalmente por MARTIN BALERIOLA JORGE MANUEL -07238112N Fecha: 2023.04.28 13:32:00 +02'00'



### Viso Farmaceutica, S.L.U.

Statement of Comprehensive Income	Sch	31/03/2023	31/03/2022
		EUR	EUR
INCOME		IFRS	IFRS
Operating Revenue	x	7.737.995	5.633.198
Other income	Y	145.962	129.499
Total		7.883.957	5.762.698
Materials consumed	Z	-	-
Changes in Inventories of FG and WIP	z	(125.176)	(152.437)
Purchase of Traded Goods	z	4.811.985	2.682.024
Employee benefit expenses	AA	1.242.971	1.036.134
Other expenses	AB	1.467.221	1.756.703
Depreciation, amortisation and impairment of non-financial assets	AC	147.852	137.411
Total		7.544.854	5.459.835
Operating profit		339.103,45	302.862,51
Finance costs	AD	8.212	2.915
Finance income	AE	-	-
Profit/(Loss) before tax		330.891	299.948
Current tax expenses	AF	83.196	74.787
Deferred tax expenses	AF	(1.334)	(107)
Total Tax expenses		81.862	74.680
Profit/(Loss) after tax from continuing operations		249.030	225.267



Viso Farmaceutica, S.L.U.

### Schedule - X

#### Х Income from operations

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Sale of goods and out licensing of Intangible assets	7.715.481	5.626.257
other operating revenue	22.515	6.941
Income from services	-	-
	7.737.995	5.633.198

#### Schedule - Y

#### Other income

Other income is summarised as follows:

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Dividend on short term investments		
Profit on sale of short term investments		
Cross charge intercompany	145.962	129.499
Exchange Gain	-	-
Profit on Sale of Business	-	-
Miscellaneous income	-	-
Interest income	-	-
Total	145.962	129.499

#### Schedule - Z

#### Z Material Consumed

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Consumption of Raw Material		
Consumption of Packing Material		
Total	-	-

#### Schedule - Z

#### Z Changes in Inventory of FG and WIP

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Changes in Inventory of FG and WIP	(125.176)	(152.437) -
Total	(125.176)	(152.437)

### Z

Particulars	31/03/2023	31/03/2022/
	EUR	EUR /
	IFRS	IFRS
	-	1-2

Purchase of Traded Goods	4.441.383	2.249.525
Inventory Write off	370.601	432.499
Total	4.811.985	2.682.024
	4 686 809	2 529 586

#### Schedule - AA

### AA Employee benefit expenses

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Salaries and bonus	1.224.767	1.020.176
Contribution to provident fund and other funds	1.320	5.160
Staff welfare expenses	16.885	10.798
Retirement benefits		
Total	1.242.971	1.036.134

# Schedule - AB

AB	Other	Expenses	

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Power, Fuel and Water charges		
Rent, Rates & Taxes	60.920	72.212
Expense relating to short-term leases		
Expense relating to leases of low value assets	674	594
Sales Promotion Expenses	432.917	531.516
Provision for Doubtful Debts	-	-
Travelling expenses	66.343	24.787
Auditors remuneration	14.628	15.750
Freight Outward	122.644	48.806
Insurance	128	642
Repairs and Maintenance	19.768	16.9 <b>1</b> 5
Telephone expenses	10.078	7.446
Other Manufacturing Expenses	-	-
Other Employee benefits	-	-
Product Registration Expenses	-	-
Legal & Professional fees	495.179	843.196
Car Rent & Fuel	-	-
Other operating expenses	232.629	180.752
Test and Trials expenses	-	-
Foreign Exchange loss	-	888
Conference Expensed	-	-
Printing & Stationery	3.294	1.976
Subscription	-	-
Postage & Telegram	3.332	2.362
Electricity Charges	-	-
Recruitment	-	-
Labour Charges	-	-
Regulatory Exp	-	-
New Product Introdu Exp	-	
Consumable R&D	-	-/
Consumption of stores and spares	-	-
Commission on Sales	-	f-
Loss on Sale of Assets	-	I + //

Bank Charges	4.686	8.861
Selling & Marketing Exp	-	-
Total	1.467.221	1.756.703

#### Schedule - AC

### AC Depreciation, amortisation and impairment of non-financial assets

Particulars	31/03/2023	31/03/2022
	EUR	EUR
Depreciation, amortisation and impairment of non-financial as:	IFRS	IFRS
	147.852	137.4 <b>1</b> 1
	147.852	137.411

#### Schedule - AD

### AD Finance income

Finance income is analysed as follows:

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Interest income on		
Inter company balances		
Interest Income on Fixed Deposits	-	-
Other Interest income	_	_
Total	-	

#### Schedule - AE

#### AE Finance costs

Finance costs is analysed as follows:

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
- Interest expense on short term borrowings		
Term loans		
Cash credit		
Interest Expense - Inter company		
Interest Expense - Others	8.212	2.915
Other Financial Expenses		
Total	8.212	2.915

#### Schedule - AF

AF Income tax (expense)/credit

Particulars	31/03/2023	31/03/2022	
	EUR	EUR	
	IFRS	IFRS	
Current income tax	83.196	74.787	
Deferred tax	(1.334)	(107)	
Prior period income tax			
Total	81.862	74.680	

ALESCO PARTNERS

#### A Cash and cash equivalents

Cash and cash equivalents include the components as follows:

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Cash on hand	152	152
Cash in current accounts	1.019.937	712.041
Cash in deposit accounts	-	-
Mutual fund deposit in liquid money market	-	-
Fund-in-transit	-	-
Total	1.020.088,8	712.192,5

#### B Restricted Cash

Restricted cash comprise the following;

F	Particulars	31/03/2023	31/03/2022
	•	EUR	EUR
		IFRS	IFRS
Current			
Dividend Account		-	-
Time Deposits			
Total		-	-
Non-current		-	-
Time deposits			
Total		-	-

### C Trade receivables [other receivables can be merged here, if material]

The carrying amount of trade receivables are analysed as follows:

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Accounts receivables	1.690.394	1.342.244
Inter company receivables	31.622	42.737
Provision for doubtful debts	-	-
Net trade receivables	1.722.016	1.384.982

#### D Inventories

Inventories recognised in the statement of financial position can be analysed as follows

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Raw Materials	-	/-/
Packing Material	-	1 - /4
Semi-Finished Goods	-	E
	·	\ ALE

Total	1.573.185	1.448.009
Others		-
Others		
Work-in-Process	-	-
Finished Goods	1.573.185	1.448.009

### E Short term financial assets

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Other receivables	2.288	_
Short term deposits	-	_
Total	2.288	

### F Other current assets

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Input taxes receivables	35.862	72.887
Advance to Vendors	-	-
Prepayment and other advances	-	~
Export incentives	-	-
Total	35.862	72.887

G Property, Plant and Equipment

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Gross Block	137.991	114.658
less: Accumulated depreciation	(94.545)	(78.863)
Net Block	-	-
Capital work in progress	_	_
Total	43.445	35.795

59.554

41.066

H Other Intangible assets

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Intangible Gross Block	200.997	164.776,24
less:Intangible Accumulated depreciation	(123.325)	(95.439,76)
Net Block	-	**
Capital work in progress	-	-
Total	77.672	69.336

H1	Right of use assets		
	Particulars	31/03/2023	31/03/2022/
		Local Currency	Local Currency
		IFRS	IFRS //

PARTNERS

Right of use assets Right of use Accumulated depreciation Net Block	300.452,00 (100.355)	314.268 (182.652)
	200.097	131.616

H2 Lease liability - current

Particulars	31/03/2023	31/03/2022
	Local Currency	<b>Local Currency</b>
	IFRS	IFRS
Lease liability - current	95.912	62.816
Total	95.912	62.816

H3 Lease liability - non current

Particulars	31/03/2023	31/03/2022
	Local Currency	Local Currency IFRS
	IFRS	
Lease liability - non current Others	111.204	70.026
Total	111.204	70.026

#### I Goodwill

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
opening balance		
Acquired through business combination		
Impairment loss recognised		
Effect of translation adjustments		
closing balance	-	-

#### J Non-current tax assets

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Advance tax	-	376
Total	-	376

#### L Non Current financial assets

Long term financial assets comprise of the following:

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Time Deposits	127.349	136.340

ALESCO PARTNERS

Bonds	-	-
Available-for-sale financial assets	-	
Investments in listed and unlisted securities	-	-
Prepayment and other advances Long Term	-	-
Long-term inter company loan	-	-
Investments in Subsidiaries	-	-
Total	127.349	136.340

M Trade payables

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Sundry creditors	888.810	1.032.791
Inter Company creditors	1.453.199	964.034
Acceptances		-
Total	2.342.009	1.996.825

### N Current tax liabilities

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Previous year tax	ļ	-
Provision for Tax	43.452	74.787
Total	43.452	74.787

O Short-term borrowings

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Short-term borrwings Working capital facilites	-	-
Total		

P Current portion of borrowings

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Current portion of long-term borrowings Inter Company loan	-	
Total	-	_

### Q Other current liabilities

Other current liabilities are summarized as follows:

Particulars Particulars	31/03/2023	31/03/2022/
	EUR	EUR /



	IFRS	IFRS
Advances received from customer	-	-
ncome received in advance	-	-
Statutory dues	42.994,42	39.171
hare Application Money		
otal	42.994	39.171

### R Short-term financial liabilities

Other current liabilities are summarized as follows:

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Employee dues	127.791	110.933
Sundry creditors for capital Goods	-	6.203
Interest accrued but not due	-	-
Accrued Expenses	309.288	149.117
Lease payable - ST	-	-
Total	437.079	266.253

### **S** Provisions

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Provision for compensated absences	-	_
Provision for gratuity benefit plan	-	-
Provision for Employee benefits	-	_
Total	-	-

T Long Term Borrowing

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Notes payable	-	
Term loan from banks	-	-
Inter company loan	-	_
Total	-	-

U Other liabilities (Non-Current)

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Total	-	-

V	Long	term	financial	liabilities
---	------	------	-----------	-------------

Particulars	31/03/2023	31/03/2022
	EUR	EUR



	IFRS	IFRS
Security Deposits	-	-
Security Deposits Lease payable - LT	-	-
Total	-	-

W Equity

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Equity attributable to owners of the parent:		
Share capital	3.000	3.000
Add- Share issued during the year	3.000	3.000
	3.000	3.000
Amalgamation reserve	- 1	-
Currency translation reserve		-
Reserve & Surplus	- 1	-
Retained earnings	- 1	-
Profit & Loss balance	1.478.856	1.253.588
Addition during the period	-	-
Current period profit	249.030	225.267
Exchnage Fluctuation Reserve	-	-
Components of Defined Employee benefit cost	- 1	-
Transfer to General reserve	- 1	-
General reserve	-	-
	1.727.886	1.478.855
Non Controlling Interest	-	-
Total Equity	1.730.886	1.481.855
	-	(0,0

X Current tax assets

Particulars	31/03/2023	31/03/2022
	Local Currency	Local Currency
	IFRS	IFRS
Advance Tax		
Total	-	-

Y Deferred tax assets

Particulars	31/03/2023	31/03/2022
	EUR	EUR
	IFRS	IFRS
Deferred tax assets	1.533	200
Total	1.533	200

Particulars	EUR 31/03/2023	EUR 31/03/2022
Farticulars	31/03/2023	31/03/2022
A) CASH INFLOW / (OUTFLOW) FROM OPERATING ACTIVITIES		
Profit before tax	330.891	299.948
Adjustments to reconcile profit before tax to net cash provided by operating activities:		
	147.050	107 411
Depreciation and amortisation Employee share based compensation	147.852	137.411
Industrial and the second seco		
Interest expense - Interest expense - Intercompany	-	**
- Interest expense - Other than Intercompany		
I		
Interest income - Interest income - Intercompany		
- Interest income - Other than Intercompany	-	_
Divident Income (Profit)/Loss on sale of fixed assets		-
(Profit)/Loss on sale of inxed assets (Profit)/Loss on sale of enterprise	-	-
(Profit)/Loss on sale of investments	-	-
Employee benefit obligation	-	-
Provision for bad and doubtful debts	-	-
Unrealised foreign exchange (gain)/loss	-	-
Operating profit before changes in operating assets and liabilities	478.744	437.358
Changes in operating assets and liabilities		
- (Increase)/ Decrease in trade receivables	(337.034)	271.026
- (Increase) / Decrease in trade receivables - Intercompany	11.116	291.807
- (Increase) / Decrease in trade receivables - Other than Intercompany	(348.150)	(20.781
- (Increase) / Decrease in other assets and short term fin Assets		
- (Increase) / Decrease in other assets and short term fin Assets - Intercompany	-	
- (Increase) / Decrease in other assets and short ther fin Assets- Other than Intercompany	34.737	482.324
	(105 176)	(150.425
-(Increase)/ Decrease in inventories	(125.176)	(152.437
- Increase/ (Decrease) in trade payables	345.184	(894.653
- (Increase) / Decrease in trade payables - Intercompany	489.165	(1.292.975
- (Increase) / Decrease in trade payables - Other than Intercompany	(143.981)	398.322
- Increase/ (Decrease) in other liablities and other financial liabilities	-	
- (Increase) / Decrease in other liabilities and other financial liabilities - Intercompany	-	_
- (Increase) / Decrease in other liabilities and other financial liabilities- Other than Interc	182.862	(2.096.441
Net changes in operating assets and liabilities	100.573	(2.390.18)
- Income taxes paid	(114.155)	(2.090.181
Net cash from operating activities	465.161,92	(1.952.822,51
(B) CASH INFLOW / (OUTFLOW) FROM INVESTING ACTIVITIES		
Restricted Cash	-	
Nouther Casil	_	
Interest received		
- Interest received - Intercompany	-	-
- Interest received - Other than Intercompany	-	
	-	-
Dividend received		(41.06)
Dividend received Payments for purchase of property, plant and equipment and intangible assets	(59.554)	(41.06)
Dividend received	(59.554)	(41.06)
Dividend received Payments for purchase of property, plant and equipment and intangible assets Proceeds from sale of property, plant and equipment		
Dividend received Payments for purchase of property, plant and equipment and intangible assets	-	
Dividend received Payments for purchase of property, plant and equipment and intangible assets Proceeds from sale of property, plant and equipment Investments in subsidiaries	-	3.147

PARTNERS

Share application money paid	-	-
Net cash used in investing activities	(50.564)	(37.919)
(C) CASH INFLOW / (OUTFLOW) FROM FINANCING ACTIVITIES		
Proceeds from long term borrowings		
- Proceeds from long term borrowings - Intercompany		-
- Proceeds from long term borrowings - Other than Intercompany	-	
Repayments of long term borrowings		
- Repayments of long term borrowings - Intercompany		-
- Repayments of long term borrowings - Other than Intercompany	-	
Proceeds from short term borrowings		
- Proceeds from short term borrowings - Other than Intercompany	-	-
Repayments of short term borrowings		
- Repayments of short term borrowings - Other than Intercompany	-	-
Proceeds/ (Repayment) of working capital facilities	-	_
Interest paid		
- Interest paid - Intercompany	-	-
- Interest paid - Other than Intercompany	-	
Proceeds from fresh issue of		
- Share capital including securities premium (net of issue expenses)	-	
Payment of principle amount of lease liability	(98.491)	(88.046)
Payment of interest amount of lease liability	(8.212)	(2.915)
Transaction with non-controlling interest		
Stock compensation expenses	-	-
Dividend paid (including tax on dividend)	-	-
Net cash from financing activities	(106.703)	(90.961)
Effect of exchange rate changes on cash		
Net increase / (decrease) in cash and cash equivalents	307.896	(2.081.703)
Cash and cash equivalents at the beginning of the year	712.192	2.793.895
Cash and cash equivalents acquired on Merger		
Cash and cash equivalents at the end of the year	1.020.088	712.193
As per Balance sheet	1.020.088	712.192



#### Lease Liabilities

Particulars	As at 31 March 2023	As at 31 March 2022
Non-current	(Amt in EUR)	(Amt in EUR)
- Buildings	89.127,00	0,00
- Pant and Equipments		
- Furniture & Fixtures		
- Office Equipments		
- Vehciles	22.077,00	70.026,00
	111.204,00	70.026,00
Current		
- Buildings	63.248,00	18.729,00
- Pant and Equipments		
- Furniture & Fixtures		
- Office Equipments		
- Vehciles	32.664,00	44.087,00
	95.912,00	62.816,00
Total	207.116,00	132.842,00

Maturity analysis	As at 31 March 2023	As at 31 March 2021	
	(Amt in EUR)	(Amt in LCY)	
Not later than 1 year	95.912,00	62.816,00	
Later than 1 year and not later than 5	111.204,00	70.026,00	
Later than 5 years			

The Group does not face a significant liquidity risk with regard to its lease liabilities. Lease liabilities are monitored within the Group's treasury function.



Depreciation, amortisation expenses

	Period ended	Period ended
Particulars Particulars	31 march 2023	31 March 2022
	(Amt in EUR)	(Amt in EUR)
Depreciation on tangible assets	15.683,21	17.708,74
Depreciation on Right to use assets	104.284,00	88.751,00
Amortization and impairment on intangible a	27.885,36	30.951,02
Total	147.852,57	137.410,76

0

	Period ended	
Particulars	31 march 2023	31 March 2022
	(Amt in EUR)	(Amt in EUR)
Interest expenses on		
- Term loans		
- Interest on foreign currency convertible bonds		
- Interest on senior notes and ECB facility		
- Interest expense on lease liabilities	8.212,00	2.915,00
- Others		
Total	8.212,00	1.779,00



#### Viso Farmaceutica S.L.U - Spain Notes to the Financial Statements

FAIR VALUE MEASUREMENTS

Financial instruments by category

Particulars		31 ma	rch 2023			31	March 2022	
_	FVTPL	Amortised cost	Total carrying value	Total fair value	FVTPL	Amortised cost	Total carrying value	Total fair value
Financial assets								
Trade receivables	-	1.722.016	1.722.016	1.722.016	-	1.384.982	1.384.982	1.384.982
Cash and cash equivalents	-	1.020.089	1.020.089	1.020.089	-	712.192	712.192	712.192
Non-current financial assets		127.349	127.349	127.349		136.340	136.340	136.340
Other current financial assets		2.288	2.288	2.288		-	-	-
Total	-	2.871.742	2.871.742	2.871.742	_	2.233.514	2.233.514	2.233.514
Particulars	*	31 ma	rch 2023			31	March 2022	
-	FVTPL	Amortised cost	Total carrying value	Total fair value	FVTPL	Amortised cost	Total carrying value	Total fair value
Financial liabilities								
Trade payables Borrowings	-	2.342.009	2.342.009	2.342.009	-	1.996.825	1.996.825	1.996.825 -
Other financial liabilities	-	437.079	437.079	437.079	-	266.253	266.253	266.253

Trade receivables comprise amounts receivable from the sale of goods and Services.

The management considers that the carrying value of trade receivables approximates their fair value.

2.779.088

Bank balane and cash comprise cash and short-term deposits held by the Company. The carrying amount of these assets approximates their fair value.

2.779.088

2.779.088

2.263.078

2.263.078

2.263.078

Trade and other payables principally comprise amounts outstanding for trade purchases and on-going costs. The management considers that the carrying amount of trade payables approximates to their fair value.

Fair value hierarchy:

Total

Level 2: All FVTPL financial assets and liabilities are classified under level 2 of fair value hierarchy.

Level 3: All amortised cost financial assets and liabilities are classified as level 3 of fair value hierarchy.

# Rights to use the assets

Particulars	Other Buildings	Vehicles	Other	Total
Cost				
Balance as at April 1, 2017				
- Internally developed				-
- Acquired through business combinations				- 1
- Other acquisitions				- /
- Disposals/ Transfers				-
- Translation adjustment				-
Balance as at March 31, 2018	-			- 1
- Internally developed				-
- Acquired through business combinations				-
- Other acquisitions				-
- Disposals/ Transfers				_
- Translation adjustment				_
Balance as at March. 31, 2019	_	-	-	-
- Internally developed				-
- Acquired through business combinations				
- Other acquisitions	153.940,09	44.993		198.933
- Disposals/ Transfers	155.710,07			_
- Translation adjustment				_
Balance as at March. 31, 2020	153.940	44.993	_	198.933,09
- Internally developed				
- Acquired through business combinations				
- Other acquisitions (lease modification)	17.897	36.725,00		54.622
- Disposals/ Transfers	17.657	(12.499)		(12.499)
- Translation adjustment		(==:::)		(
Balance as at March. 31, 2021	171.837	69.219		241.056
- Internally developed		0,123		
- Acquired through business combinations				
- Other acquisitions (lease modification)		108.895		108.895
- Disposals/ Transfers		(35.683)		(35.683)
- Translation adjustment		(33.003)		(33.003)
Balance as at March. 31, 2022	171.837	142.431		314.268
- Internally developed	1/1.03/	142.431	-	314.200
- Acquired through business combinations				
. 0	105 207			105 200
- Other acquisitions (lease modification)	195.297	(27.277)		195.298
- Disposals / Transfers	(171.837)	(37.277)		(209.114)
- Translation adjustment	105 207	105 155		200 452
Balance as at March. 31, 2023	195.297	105.155	-	300.452
Balance as at April 1, 2017				
- Amortisation charge for the year				
- Impairment				-
- Amotisation charge for disposals/ transfers				-
- Translation adjustment				-/
Balance as at March 31, 2018	-	-		-/

- Translation adjustment				
- Impairment - Amotisation charge for disposals/ transfers				
Balance as at March. 31, 2020	46.182	21.280		67.462
- Amortisation charge for the year	51.778,00	22.844,00		74.622
- Impairment loss	31.770,00	22.011,00		. ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
- Impairment				
- Amotisation charge for disposals/ transfers		(12.499)		(12.499)
- Translation adjustment		` 1		
Balance as at March. 31, 2021	97.960	31.625	-	129.585
- Amortisation charge for the year	55.408	33.341		88.751
- Impairment loss				
- Impairment				
- Amotisation charge for disposals/ transfers		(35.683)	116	(35.683)
- Translation adjustment				
Balance as at March. 31, 2022	153.368	29.283	-	182.653
- Amortisation charge for the year	67.293	36.991		104.284
- Impairment loss				-
- Impairment	ļ			_
- Amotisation charge for disposals/ transfer	(171.837)	(14.744)		(186.581)
	( /		AND RESIDENCE TO THE	()
- Translation adjustment				

Carrying value

Chilying ville				
At March 31, 2017	- 1	-	-	-
At March 31, 2018	-	-		-
At March. 31 2019	-	-	-	-
At March. 31 2020	107.758	23.713		131.471
At March. 31 2021	73.877	37.594	- 1	111.471
At March, 31 2022	18.469	113.148		131.616
Balance as at March. 31, 2023	146.473	53.625	-	200.097



### Viso Farmaceutica, S.L.U.

Statement of Comprehensive Income	Sch	31/12/2022	31/03/2022
		EUR	EUR
		IFRS	IFRS
Profit for the year		249.030	<sup>-</sup> 225.267
Other comprehensive income:			
Cash flow hedging			
- current year gains (losses)	1		
- reclassification to profit or loss			
Available-for-sale financial assets			
- current year gains (losses)			
- teclassification to profit or loss			
Exchange differences on translating foreign operations			
Share of other comprehensive income of equity accounted investments - reclassification to profit or loss			
Share of other comprehensive income on fair valuation of financial assets/liabilities reclassification to profit or loss			
Difference from method change 2012			
Income tax relating to components of other comprehensive income			
Other comprehensive income for the period, net of tax			
Total comprehensive income for the period		249.030	225.267
Total Comprehensive Income attributable to:			
Non Controlling Interest			
Owners of the parent		249.030	225.267



Particulars	31 th March 23						
	Third party	inter company	Total				
Revenue as per contracted price	9.975.904 €		9.975.904 €				
Adjustments	-2.237.909	145.962	-2.091.947				
Extended warranties			- €				
Loyalty points			- €				
Significant financing component			- €				
sales return	- 78.496€	-	78.496 €				
discount	- 2.181.928€	-	2.181.928€				
other	22.515 €	145.962 €	168.477 €				
Revenue from contract with customers	7.737.995	145.962	7.883.957				

7.737.995

**145.962 7.883.957** 

Particulars		31 st March 22	
	Third party	Inter company	Total
Revenue as per contracted price	7.612.359 €		7.612.359 €
Adjustments	- 1.979.161€	129.499 €	- 1.849.662€
Extended warranties			- €
oyalty points			- €
Significant financing component			- €
sales return	- 25.998€		- 25.998€
discount	- 1.915.832 €		- 1.915.832 €
other	- 37.331 €	129.499€	92.168€
Revenue from contract with customers	5.633.198	129.499	5.762.698



IFRS - income statement

		As	at 31.03.2023		As at 31.03.2022			
Provisions	Rebate	Paybac	:k	Returns	Rebate	Payback	Returns	
Balance at the Beginning of the year		0,00€	123.119	25.998	1.710.28	2 570.371	L	
Provided during the year		0,00	180.386	193.009	38.44	3 98.837	153.793	
Utilised/ reversed/Pay-out during the year		0,00	-98.711	-114.513	-1.748.72	5 -546.089	-127.794	
Balance at the end of the year		0,00 €	204.794,37 €	104.494,04 €		0 123.119	25.998	
Check		0,00	0,00	0,00	0,0	0,00	0,00	



									EUR
	Share Capital	APIC/Share Premium	Available for-sale financial assets	Retain earnings	Reserves & Surplus	Revaluatio n reserve	Currency translation reserve	Total attributab le to owners of parent	Total equity
Balance as at march, 2021	3.000	-	-	1.253.586	-	-		-	1.256.58
Dividends									
Issue of share capital									
Transactions with owners									
Profit for the year				225.267					225.20
Other comprehensive income:									
Cash flow hedging									
Income tax relating to components of other			1						
comprehensive income									
Total comprehensive income for the year									
Balance at March 31, 2022	3.000	-	-	1.478.853	-	-		-	1.481.85
Dividends									
Issue of share capital						}			
Transactions with owners									
Audit adjustment regarding the difference in the OB									
Profit for the year				249.030					249.03
Other comprehensive income:								'	
Cash flow hedging									
- current year gains (losses)									
- reclassification to profit or loss									
Available-for-sale financial assets									
- current year gains (losses)				Ì					
- reclassification to profit or loss									
Difference from method change									
Exchange differences on translating foreign									
operations									
Income tax relating to components of other									
comprehensive income									
Total comprehensive income for the year Balance at a March 31, 2023	3.000			1.727.883					1.730.8



## Viso Farmacéutica, S.L.U.

Descriptions	Glenmark Holding, S.A.			
Descriptions	Nos of Shares	Document Currency		
		EUR		
Opening Balance as on April 1st, 2022				
Add- Share Issued during the Quarter/Period/ Year with (NOS and Value)	3000	3000		
Other Adjustments				
Realized exchange Gain/(loss)				
Others- Please specify				
Closing Balance	3.000	3.000		



											EUR
Particulars	Building	Other Premisses	Vehicles	Plant & Machinary	Furniture	Computers	Equipment & Aircondition	Office Equipment	Freehold Land	CWIP	Total
Cost											
Balance at april 1, 2020  - Acquisitions through business combinations						25.638	64.660	0	-	-	90.298
- Other acquisitions - Disposals/Transfers						2.238	1.010				3.248
- Translation adjustment						2.205	(2.205)				
Balance as at March 31, 2021						30.081	63.465	-	-		93.546
- Acquisitions through business combinations											•
- Other acquisitions - Disposals/Transfers						16.154	4.958				21.112
- Translation adjustment											-
Balance as at March,31 2022	-		-			46.235	68.423			-	114.658
- Acquisitions through business combinations											
<ul><li>Other acquisitions</li><li>Disposals/Transfers</li></ul>						12.758	10.575				23.333
- Translation adjustment											
Balance as at March,31 2023	-		-			58.992	78.998			-	137.991
Accumulated Depreciation											
Balance at april 1, 2020						16.472	26.807			- 1	43.279
<ul> <li>Depreciation charge for the year</li> <li>Impairment loss recognized</li> <li>Disposals/Transfers</li> </ul>						6.256	11.620				17.876
- Translation adjustment						21.636	39.519			-	61.154,37
Balance as at March 31, 2021	-		-			4,770	12.578			-	17.709
Depreciation charge for the year     Impairment loss recognized     Disposals/Transfers     Translation adjustment						4,770	12.376				-
Balance as at March,31 2022	-					26.406	52.096			-	78.863
BOOK AND THE RESERVE AND ADDRESS OF THE PARTY OF THE PART	=				+	5.638	10.044				15.682
Depreciation charge for the year     Impairment loss recognized     Disposals/Transfers						5.600	201011				
- Translation adjustment						32.044	62.141			-	94.545
Balance as at March,31 2023						32.044	62.141				74.343
Carrying value											
At April 1, 2020						8.445	23.947				32.392
Ar March 31, 2021	1 .					3.282	11.235			-	14.516
At March 31, 2022			3			19.829	16.327				36.156
Balance as at March,31 2023	-					26.949	16.858			-	43.445



## Other intangible assets

Particulars	Computer software	Other	Intangibles under constr.	Total
Cost				
Balance as at April 1, 2017	24.477			24.477
- Internally developed	6.499			6.499
- Acquired through business combinations				-
- Other acquisitions				-
- Disposals/ Transfers				-
- Translation adjustment				-
Balance as at March 31, 2018	30.976			30.976
- Internally developed	34.238			34.238
- Acquired through business combinations				
- Other acquisitions				-
- Disposals/ Transfers				-
- Translation adjustment				
Balance as at March. 31, 2019	65.215		_	65.214,74
·				20.798
- Internally developed	20.798,35			
- Acquired through business combinations				_
- Other acquisitions				-
- Disposals/ Transfers				<u>-</u>
- Translation adjustment	86.013		_	86.012.00
Balance as at March,31 2020		100	-	86.013,09 58.808,00
- Internally developed	58.808,00			50.000,00
- Acquired through business combinations				
- Other acquisitions				
- Disposals/ Transfers				
- Translation adjustment	144 001			444.024.00
Balance as at March 31, 2021	144.821			144.821,09
- Internally developed	19.955			19.954,70
- Acquired through business combinations				
- Other acquisitions				
- Disposals/ Transfers				
- Translation adjustment				
Balance as at March 31, 2022	164.776	-	-	164.776
- Internally developed	36.221			36.221,00
- Acquired through business combinations				
- Other acquisitions			İ	
- Disposals/ Transfers				
- Translation adjustment				
Balance as at March 31, 2023	200.997	-	-	200.997
Amortisation and impairment				
Balance as at April 1, 2017	4.170			4.170
- Amortisation charge for the year	6.356			6.356
- Impairment	0.550			

- Amotisation charge for disposals/ transfers	1	1		. 1
- Translation adjustment				_
Balance as at March 31, 2018	10.526	-		10.526
- Amortisation charge for the year	10.268			10.268
- Impairment loss				_
- Impairment				. 1
- Amotisation charge for disposals/ transfers				_
- Translation adjustment				_
Balance as at March. 31, 2019	20.794			20.794
l F	18.498			18.498
- Amortisation charge for the year	10.170			_
- Impairment loss				. 1
- Impairment				_
- Amotisation charge for disposals/ transfers				
- Translation adjustment	20.202			20.202
Balance as at March,31 2020	39.293	-		39.293
- Amortisation charge for the year	24.103,64			24.103,6
- Impairment loss				
- Impairment				
- Amotisation charge for disposals/ transfers				
- Translation adjustment	1.092			1.092
Balance as at March 31, 2021	64.488			64.488
- Amortisation charge for the year	30.951			30.951
- Impairment loss				-
- Impairment				-
- Amotisation charge for disposals/ transfers				-
- Translation adjustment				
Balance as at March 31, 2022	95.439	-	-	95.439
- Amortisation charge for the year	27.885			27.885
- Impairment loss				-
- Impairment				-
- Amotisation charge for disposals/ transfers				-
- Translation adjustment				
Balance as at March 31, 2023	123.325	-	-	123.325
Carrying value				
At March 31, 2017	20.307	-	-	20.307
At March 31, 2018	20.450	-	-	20.450
At March. 31 2019	44.420	-	-	44.420
At March. 31 2020	46.720	-	-	46.720
At March. 31 2021	80.333			80.333
At March. 31 2022	69.336			69.336
Balance as at March 31, 2023	77.672	, ,		77.672



#### K Deferred tax assets and liabilities

Deferred taxes arising from temporary differences and unused tax losses are summarized as follows:

Local Curr	rer	C
------------	-----	---

							Local Currency
		31/03/2023	Recognised in	Recognised in	Recognised in	Recognised	31/03/2022
			other comprehensive	business	business	in profit and loss	
			income	combination	combination	account	
Deferred tax assets							
	Intangible assets	-					
	Property, plants and equipments	-					
	Retirement benefits and other employee benefits	-					
	Straight lining of rent						
	Minimum Alternative Tax credit entitlement	-					
	Impact of change on tax rates from previous year	-					
	Unused tax losses	-					
	Others	201				1.332,00	1.533
	Provision for credit losses	-				-	
	Total	201				1.332,00	1.53
Deferred tax liabilities							
	Tangible, Intangible assets	_					
	Financial Investment	_					
	Other current assets	_					
	Total					-	
						***************************************	
Net deferred tax asset	, de	201,00				1.332	1.533



Amounts recognized in statement of profit and loss	EUR	EUR	
	Year ended 31	Year ended 31	
	march 2023	March 2022	
Current income tax	83.196	74.787	
Deferred income tax charge, (net)	(1.334)	(107,00)	
Origination and reversal of temporary differences			
Tax expense for the year	81.862	74.680,25	

(b) Amounts recognized in other comprehensive income

	Year e		Net of tax	Before tax	Year ended 31 March 2022 Tax (expense) benefit	Net of tax
	Before tax	Tax (expense) benefit	Net of tax	Before tax	rax (expense) benefit	Net of tax
Total		-		-		-

(c) Reconciliation of effective tax rate

	EUR	EUR
	Year ended 31 march 2023	Year ended 31 March 2022
Profit before tax	330.891,45	299.947,51
Tax using the Company's domestic tax rate 25%.	82.722,86	74.986,88
Tax effect of income subject to lower tax rate		
Deferred tax on lease not recognised in PY		
Tax effect of amounts which are not deductible in calculating taxable income		
Not allowable expenses - permanent difference	(861,00)	(307,00)
Translation difference		
Tax expense as per statement of profit and loss	81.861,86	74.679,88

Movement in deferred tax balances 0 - 0



#### Viso Farmaceutica S.L.U - Spain Notes to the Financial Statements

#### 29. RELATED PARTY DISCLOSURES

# a) Related party relationships where transactions have taken place during the year

 $\label{thm:continuous} \mbox{Holding / Subsidiary/ associated company over which key managerial personnel exercise significant influence}$ 

Glenmark Holding S.A., Switzerland

Glenmark Pharmaceuticals Europe Limited -U.K.

Glenmark Pharmaceuticals Distributors S.R.O,Czech Republic

Glenmark Pharmaceuticals Limited -India

Glenmark Pharmaceuticals S.R.O,Czech Republic

Glenmark Lifesciences - India

Glenmark Pharmaceuticals Sp. z o.o. Polonia

	Fransaction with related parties during the year	average march 23 closing EUR 31/03/2023	Average March 22 Closing March EUR 2021/22
1.	Sale of Goods and Services to		
	Glenmark Pharmaceuticals Limited -India	-	
	Glenmark Lifesciences - India	-	
	Glenmark Pharmaceuticals Europe Limited -U.K.	-	
	Glenmark Pharmaceuticals Distributors S.R.O,Czech Republic	-	
	Glenmark Pharmaceuticals S.R.O,Czech Republic	-	-
2.	Purchase of goods from ;		
	Glenmark Pharmaceuticals Europe Limited -U.K.	22.127	464.903
	Glenmark Pharmaceuticals S.R.O,Czech Republic	3.990.100	1.821.559
2.	Expenses incurred on behalf of ;		
	Glenmark Pharmaceuticals Limited -India	(315.012)	-
	Glenmark Lifesciences - India	(12.824)	129.499
	Glenmark Pharmaceuticals Europe Limited -U.K.	1.708	160.376
	Glenmark Pharmaceuticals S.R.O,Czech Republic	-	-
3.	Expenses incurred by ;		
	Glenmark Pharmaceuticals Europe Limited -U.K.	344	187.035
	Glenmark Pharmaceuticals, S.R.O	196.117	132.465
	Glenmark Pharmaceuticals Sp. z o.o.	-	-
4.	Recharge of penalties for failure to supply	-	-
	Glenmark Pharmaceuticals Europe Limited -U.K.		
5.	Interest on loan taken		
	Glenmark Holding S.A.,Switzerland		
6.	Loan repaid to		
	Glenmark Holding S.A., Switzerland		

#### c) Related party balances

Receivable/ (Payable) from/ (to) subsidiary / associated companies		
Glenmark Pharmaceuticals Europe Limited -U.K. (Net)	(168.053)	(462.304)
Glenmark Pharmaceuticals Limited -India		-
Glenmark Pharmaceuticals S.R.O,Czech Republic	-	-/ /
Glenmark Pharmaceuticals Distributors S.R.O,Czech Republic	-	-/ //\\ \
Glenmark Pharmaceuticals S.R.O,Czech Republic	(1.283.438)	(501,730)
Glenmark Lifesciences - India	29.914	42,737
		/ ALESCO /
		PARTNERS

Glenmark Pharmaceuticals, S.R.O Glenmark Pharmaceuticals Sp. z o.o.	196.117,05	132.465,32
Marketing Expenses		

(c) Balances at the year end: EUR EUR

Fellow subsi	diary	
31 March 2023	31 March 2022	
1.708	(0)	
_	- '	
29.913,86	42.737,48	
-	-	
169.761	462.303,59	
	,	
1.283.438	501.729,74	
-	C	
	1.708 - 29.913,86 - 169.761	

